In fiscal year 2020/21, ZEISS achieves highest revenue yet in its 175-year history at 7.5 billion euros (+20% compared to prior year) – including EBIT at 1.5 billion euros (+ 557 m euros as compared to prior year)
- All four ZEISS segments achieve double-digit revenue growth
- Significant investments in research and development pay off – with 13% of revenue at a consistently high level
- Headcount rises by 10 percent to 35,375
Oberkochen, Germany | 15 December 2021 | ZEISS Group
The ZEISS Group ended fiscal year 2020/21 (end of reporting period: 30 September 2021) on an excellent note: its revenue rose by 20% to 7.529 billion euros (previous year: 6.297 billion euros). Over 90% of this sum was generated in markets outside Germany. Earnings before interest and tax (EBIT) also achieved a new high, reaching 1.479 billion euros (prior year: 922 million euros). The EBIT margin was 20%. Incoming orders increased to 8.974 billion euros (prior year: 6.814 billion euros).
“2021 is a very special year for ZEISS. 175 years ago, Carl Zeiss laid the foundations for a company that has grown into a technology leader and proves time and again that it can push the limits of what is technically feasible. We are of course particularly delighted to have achieved record results once again in our anniversary year,” said Dr. Karl Lamprecht, ZEISS President and CEO. “While there is certainly room to improve in a number of areas, double-digit growth across all four ZEISS segments demonstrates that we are on the right path thanks to our balanced portfolio and our ZEISS Agenda. Upwards of 35,000 employees, a high capacity for innovation, as well as excellently aligned segments and all regions contribute to this growth.”
Segment development
| Revenue (in billions of euros) | |||
| 2020/21 | 2019/20 | Change (adjusted for currency effects) | |
| Semiconductor Manufacturing Technology | 2.298 | 1.833 | +25% (+26%) |
| Industrial Quality & Research | 1.801 | 1.640 | +10% (+12%) |
| Medical Technology* | 1.951 | 1.647 | +18% (+ 22%) |
| Consumer Markets | 1.394 | 1.099 | +27% (+30%) |
* Not identical to the Carl Zeiss Meditec Group
Business at ZEISS’ four segments has developed very well over the past fiscal year.
The Semiconductor Manufacturing Technology segment achieved another record result in the past fiscal year. There has been sustained high demand for the innovative extreme ultraviolet (EUV) lithography systems and deep ultraviolet (DUV) lithography systems. Chips produced using EUV technology are deployed in the latest smartphones. The next EUV generation, High-NA EUV, will enable the production of even higher-performance and more energy-efficient chips at a lower cost.
The Industrial Quality & Research segment benefitted from market stabilization. The microscopy solutions business continued to develop well and achieved two-digit growth. Higher demand was recorded in the life sciences and electronics. The business for industrial quality assurance solutions has recovered. Sizeable investments in alternative drive technologies for the automobile industry offer new growth potential for ZEISS: microscopy and quality assurance solutions are increasingly deployed in battery research and in quality assurance for battery production.
The Medical Technology segment reported a considerable increase in its turnover despite a fraught situation in its supply chain. The segment benefitted from strong growth in recurring revenues like consumables, implants and services in ophthalmology. Microsurgery sales also continued to recover. At the end of the fiscal year innovations were unveiled for cataract and refractive laser surgery and for digitalization.
The Consumer Markets segment has recovered from the impact of the COVID-19 pandemic and generated clear growth. In ophthalmology, innovations related to ZEISS branded lenses in particular, as well as digital products and services and rising purchasing power in emerging countries, all contributed to this growth. The conditions for logistics and delivery reliability will remain challenging. Innovations for nature observation and hunting, and the expansion of strategic partnerships for mobile photography, have allowed the company to compensate for declining demand for camera and interchangeable lenses.
Dr. Karl Lamprecht, CEO Carl Zeiss AG
Dr. Christian Müller, CFO Carl Zeiss AG
Key figures
Free cash flow amounted to 1.125 billion euros (prior year: 518 million euros). The company’s equity rose by 28 percent to 5.494 billion euros (30 September 2020: 4.287 billion euros) as compared to fiscal year 2019/20, which equates to company equity of 52% (prior year: 47%).
Expenditure on research and development was further increased and amounted to 943 million euros, or roughly 13 percent of revenue (prior year: 812 million euros). This was done primarily through the ZEISS Semiconductor Manufacturing Technology segment’s development roadmap as well as in the areas of digitalization and product innovation.
Investments in property, plant and equipment were ramped up to 756 million euros in the reporting period (prior year: 484 million euros), as compared to depreciations totaling 263 million euros (prior year: 256 million euros).
At the end of the reporting period on 30 September 2021, net liquidity totaled 2.120 billion euros.
Distinct revenue growth was achieved in the Americas and APAC regions in particular. Growth was also reported in the EMEA region. ZEISS’ global structure therefore contributed to stability once again.
“To continue impressing customers with our innovations, we are making sizeable investments in research and development and have taken major steps in the name of sustainability,” said Dr. Christian Müller, Chief Financial Officer of Carl Zeiss AG. “Sustainability is an integral part of our strategic ZEISS Agenda 2025. Five different working groups are focusing on topics like green infrastructure, green business models and social engagement in a bid to achieve outcomes that are both far-reaching and sustainable,” said Müller. “That’s because ZEISS aims to operate in a carbon-neutral way in its own activities worldwide by 2025.”
ZEISS’ targeted innovation strategy, combined with substantial expenditure on research and development and other investments, is a cornerstone of the company’s accelerated growth. This also includes the targeted expansion of infrastructure, for example at the headquarters in Oberkochen, the ZEISS high-tech site construction project in Jena, and the newly opened ZEISS Innovation Center in Dublin (California, USA).
ZEISS’ new collaborations and acquisitions in the past fiscal year include its partnership with global technology player vivo in the area of mobile imaging, which was announced in December. This partnership focuses on a jointly developed camera system.
Moreover, ZEISS acquired a majority stake in arivis AG in order to expand its offering in the microscopy business with innovative 3D and big data software solutions. This is how the company is bolstering its software skills and market position in the field of 3D visualization and analysis technology.
ZEISS recently announced its acquisition of Capture 3D, a top US-based company that distributes solutions for optical 3D metrology. With the completion of this transaction, Capture 3D became part of the ZEISS Industrial Quality & Research segment.
At the end of the fiscal year (30 September 2021) ZEISS had a global workforce of 35,375 employees (prior year: 32,201 employees). Headcount thus increased by 10% as compared to 30 September 2020. The ZEISS Semiconductor Manufacturing Technology segment experienced the strongest growth and hired over 800 new people.
Outlook
ZEISS is closely monitoring the uncertainty created by the ongoing COVID-19 pandemic and the risks resulting from bottlenecks in the supply chain. However, the ZEISS strategy is aligned with long-term megatrends such as digitalization, demographic change and new mobility trends. The very good results achieved in the fiscal year show that all ZEISS segments are able to sustainably maintain their successful growth trajectories. ZEISS therefore expects to see a moderate rise in revenue for fiscal year 2021/22, with an EBIT yield that remains significantly
over 10%.
Press Contact
Jörg Nitschke
Group Spokesman
ZEISS Group
Phone: +49 7364 20-3242
joerg.nitschke@zeiss.com
About ZEISS
ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totaling 7.5 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (status: 30 September 2021).
For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world’s leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.
With a portfolio aligned with future growth areas like digitalization, healthcare and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company’s significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS’ technology and market leadership. ZEISS invests 13 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future.
With over 35,000 employees, ZEISS is active globally in almost 50 countries with around 30 production sites, 60 sales and service companies and 27 research and development facilities. Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG.
